Codexis reiterated earnings guidance for 2022. Total revenues are expected to be in the range of $152 million to $158 million, an increase of nearly 50% at the midpoint compared to 2021; excluding revenue from Pfizer in both periods, revenue growth is projected to be 10% or more. Product revenues are expected to be in the range of $112 million to $118 million, including approximately $75 million to $80 million related to sales of CDX-616 to Pfizer to manufacture PAXLOVID.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.26 USD | -7.39% | -3.55% | +6.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.89% | 230M | |
+51.85% | 57.87B | |
+41.70% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Codexis Reiterates Earnings Guidance for 2022